Disseminated intravascular coagulation in solid tumors

Clinical and pathologic study

S. Sallah, Jim Wan, N. P. Nguyen, L. R. Hanrahan, G. Sigounas

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Disseminated intravascular coagulation (DIC) is a well known hemostatic complication of solid tumors. We evaluated the occurrence of DIC in 1117 patients with solid tumors. Of these patients, 76 (6.8%) were diagnosed with DIC. There were a total of 145 bleeding and clotting episodes reported in the 76 patients. Thrombocytopenia, hypofibrinogemia, elevated D-dimer and fibrinogen degradation products were the most common coagulation abnormalities encountered in patients with DIC. In multivariate analysis, older age (p = .0001), male gender (p = .009), advanced malignancies (p = .027), breast cancer (p = .038) and the presence of necrosis in the tumor specimen (p = .004), emerged as independent factors significantly related to the occurrence of DIC in patients with solid tumors. Of the 76 patients, 25 (33%) achieved response to treatment of DIC as defined in the study. Patients with early stage and advanced malignancies who developed DIC had inferior survival when compared with their counterparts without DIC (p = .039 and p = .005, respectively). Taken together, this study indicates that certain clinical and laboratory features are more common in patients with solid tumors who developed DIC. The occurrence of DIC appears to have an independent effect on survival of patients with cancer. Cooperative studies are encouraged to better address the usefulness and optimal prophylactic heparin regimen in patients at risk for DIC.

Original languageEnglish (US)
Pages (from-to)828-833
Number of pages6
JournalThrombosis and Haemostasis
Volume86
Issue number3
StatePublished - Sep 22 2001

Fingerprint

Disseminated Intravascular Coagulation
Neoplasms
Clinical Studies
Survival
Hemostatics
Thrombocytopenia
Fibrinogen
Heparin
Necrosis
Multivariate Analysis
Breast Neoplasms
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Sallah, S., Wan, J., Nguyen, N. P., Hanrahan, L. R., & Sigounas, G. (2001). Disseminated intravascular coagulation in solid tumors: Clinical and pathologic study. Thrombosis and Haemostasis, 86(3), 828-833.

Disseminated intravascular coagulation in solid tumors : Clinical and pathologic study. / Sallah, S.; Wan, Jim; Nguyen, N. P.; Hanrahan, L. R.; Sigounas, G.

In: Thrombosis and Haemostasis, Vol. 86, No. 3, 22.09.2001, p. 828-833.

Research output: Contribution to journalArticle

Sallah, S, Wan, J, Nguyen, NP, Hanrahan, LR & Sigounas, G 2001, 'Disseminated intravascular coagulation in solid tumors: Clinical and pathologic study', Thrombosis and Haemostasis, vol. 86, no. 3, pp. 828-833.
Sallah, S. ; Wan, Jim ; Nguyen, N. P. ; Hanrahan, L. R. ; Sigounas, G. / Disseminated intravascular coagulation in solid tumors : Clinical and pathologic study. In: Thrombosis and Haemostasis. 2001 ; Vol. 86, No. 3. pp. 828-833.
@article{5475ec4b3a0141128bc3e4ba4c8b9657,
title = "Disseminated intravascular coagulation in solid tumors: Clinical and pathologic study",
abstract = "Disseminated intravascular coagulation (DIC) is a well known hemostatic complication of solid tumors. We evaluated the occurrence of DIC in 1117 patients with solid tumors. Of these patients, 76 (6.8{\%}) were diagnosed with DIC. There were a total of 145 bleeding and clotting episodes reported in the 76 patients. Thrombocytopenia, hypofibrinogemia, elevated D-dimer and fibrinogen degradation products were the most common coagulation abnormalities encountered in patients with DIC. In multivariate analysis, older age (p = .0001), male gender (p = .009), advanced malignancies (p = .027), breast cancer (p = .038) and the presence of necrosis in the tumor specimen (p = .004), emerged as independent factors significantly related to the occurrence of DIC in patients with solid tumors. Of the 76 patients, 25 (33{\%}) achieved response to treatment of DIC as defined in the study. Patients with early stage and advanced malignancies who developed DIC had inferior survival when compared with their counterparts without DIC (p = .039 and p = .005, respectively). Taken together, this study indicates that certain clinical and laboratory features are more common in patients with solid tumors who developed DIC. The occurrence of DIC appears to have an independent effect on survival of patients with cancer. Cooperative studies are encouraged to better address the usefulness and optimal prophylactic heparin regimen in patients at risk for DIC.",
author = "S. Sallah and Jim Wan and Nguyen, {N. P.} and Hanrahan, {L. R.} and G. Sigounas",
year = "2001",
month = "9",
day = "22",
language = "English (US)",
volume = "86",
pages = "828--833",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "3",

}

TY - JOUR

T1 - Disseminated intravascular coagulation in solid tumors

T2 - Clinical and pathologic study

AU - Sallah, S.

AU - Wan, Jim

AU - Nguyen, N. P.

AU - Hanrahan, L. R.

AU - Sigounas, G.

PY - 2001/9/22

Y1 - 2001/9/22

N2 - Disseminated intravascular coagulation (DIC) is a well known hemostatic complication of solid tumors. We evaluated the occurrence of DIC in 1117 patients with solid tumors. Of these patients, 76 (6.8%) were diagnosed with DIC. There were a total of 145 bleeding and clotting episodes reported in the 76 patients. Thrombocytopenia, hypofibrinogemia, elevated D-dimer and fibrinogen degradation products were the most common coagulation abnormalities encountered in patients with DIC. In multivariate analysis, older age (p = .0001), male gender (p = .009), advanced malignancies (p = .027), breast cancer (p = .038) and the presence of necrosis in the tumor specimen (p = .004), emerged as independent factors significantly related to the occurrence of DIC in patients with solid tumors. Of the 76 patients, 25 (33%) achieved response to treatment of DIC as defined in the study. Patients with early stage and advanced malignancies who developed DIC had inferior survival when compared with their counterparts without DIC (p = .039 and p = .005, respectively). Taken together, this study indicates that certain clinical and laboratory features are more common in patients with solid tumors who developed DIC. The occurrence of DIC appears to have an independent effect on survival of patients with cancer. Cooperative studies are encouraged to better address the usefulness and optimal prophylactic heparin regimen in patients at risk for DIC.

AB - Disseminated intravascular coagulation (DIC) is a well known hemostatic complication of solid tumors. We evaluated the occurrence of DIC in 1117 patients with solid tumors. Of these patients, 76 (6.8%) were diagnosed with DIC. There were a total of 145 bleeding and clotting episodes reported in the 76 patients. Thrombocytopenia, hypofibrinogemia, elevated D-dimer and fibrinogen degradation products were the most common coagulation abnormalities encountered in patients with DIC. In multivariate analysis, older age (p = .0001), male gender (p = .009), advanced malignancies (p = .027), breast cancer (p = .038) and the presence of necrosis in the tumor specimen (p = .004), emerged as independent factors significantly related to the occurrence of DIC in patients with solid tumors. Of the 76 patients, 25 (33%) achieved response to treatment of DIC as defined in the study. Patients with early stage and advanced malignancies who developed DIC had inferior survival when compared with their counterparts without DIC (p = .039 and p = .005, respectively). Taken together, this study indicates that certain clinical and laboratory features are more common in patients with solid tumors who developed DIC. The occurrence of DIC appears to have an independent effect on survival of patients with cancer. Cooperative studies are encouraged to better address the usefulness and optimal prophylactic heparin regimen in patients at risk for DIC.

UR - http://www.scopus.com/inward/record.url?scp=0034845299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034845299&partnerID=8YFLogxK

M3 - Article

VL - 86

SP - 828

EP - 833

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 3

ER -